ArticleProceedings of the National Academy of Sciences of the United States of America2021
Involvement of cytotoxic Eomes-expressing CD4
Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Single-cell transcriptome landscape of circulating CD4Cell genomics · 2024Pooled it
- Immune-Related Gene Variants as Modifiers of Multiple Sclerosis Severity.International journal of molecular sciences · 2026Article
- A unique CD4⁺ T cell subset expressing granzyme K is regulated by transcription factor EOMES and important for T cell-mediated intestinal inflammation.Nature immunology · 2026Article
- FES eQTL suppresses the progression of primary aldosteronism by regulating CD3 on TD CD8br immune cells: Mendelian randomization and mediation analysis.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Article
- Cytomegalovirus Drives the Development of Cytotoxic CD4Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Cytotoxic CD4Signal transduction and targeted therapy · 2026Review
- Heated tobacco and cigarette smoke modulate CD4 + T cell activation and neuroinflammation in a context-dependent manner.Journal of neuroinflammation · 2026Article
- Dermatomyositis and antisynthetase syndrome disease activity is associated with the expansion of peripheral GZMBFrontiers in immunology · 2026Article
- FreeSurfer-based amygdala subfield volumetry in long COVID and ME/CFS: clinical and immunological correlations.Frontiers in neurology · 2026Article
- VNUT-mediated ATP release suppresses T helper 1 (TScience advances · 2025Article
- Robust CD4medRxiv : the preprint server for health sciences · 2025Article
- CD4 T cells acquire Eomesodermin to modulate cellular senescence and aging.Nature aging · 2025Article
- CD4 T cell dysfunction is associated with bacterial recrudescence during chronic tuberculosis.Nature communications · 2025Article
- CD4 T cell dysfunction is associated with bacterial recrudescence during chronic tuberculosis.bioRxiv : the preprint server for biology · 2025Article
- Eomesodermin-expressing CD4 Th cells and association with multiple sclerosis progression and brain atrophy.Brain communications · 2025Article
- Apheresis for the treatment of relapses in MS and NMOSD: reduced antibody reactivities, gene expression changes and potential clinical response indicators.Frontiers in immunology · 2025Article
- Cytotoxic CD4Frontiers in immunology · 2025Article
- Recurrent fever of unknown origin and unexplained bacteremia in a patient with a novel 4.5 Mb microdeletion in Xp11.23-p11.22.Scientific reports · 2024Article
- The Current Landscape of Hypotheses Describing the Contribution of CD4+ Heterogeneous Populations to ALS.Current issues in molecular biology · 2024Article
- Oligoclonal CD4Communications biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS), a putative autoimmune disease of the central nervous system (CNS), commonly presents as relapsing-remitting MS (RRMS), characterized by recurrent episodes of peripheral disabling symptoms resulting from inflammatory CNS damage. Many RRMS patients transition to a chronic disease course with progressive neurological dysfunctions (secondary progressive MS, SPMS), with the progression rate varying between patients and over time. SPMS pathogenesis is now linked to immune-cell-mediated processes, although the mechanisms driving SPMS transition and progression remain elusive, and SPMS lacks biomarkers and effective treatments. We report the crucial involvement of cytotoxic CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.